Print
Email
Print Edition Stories
Health care industry eyes iPad
MHT talks with Tanja Dominko, WPI researcher and CellThera president
MHT talks with Grant McGimpsey, director of the WPI Center for Neuroprosthetics
Zoll Medical Corp. saw a slight jolt in revenue for its third quarter of 2010, climbing to $111.3 million versus $95.1 million for the third quarter of 2009. Profit, however, spiked to $5.7 million for the quarter, against the $1.5 million in Q3 2009.
The boost in revenue was mostly due to sales of Chelmsford-based Zoll’s defibrillators and other resuscitation devices to the pre-hospital market -- the category that encompasses first-responders -- which jumped 26.6 percent year-over-year to $51.1 million.
According to Zoll chairman and CEO Richard Packer, the growth in the pre-hospital segment was driven in large part by a large shipment to Canada, which standardized the EMS system in Newfoundland on Zoll equipment.
A drop in the military segment of its hospital business brought the overall North American hospital market down 8 percent from Q3 2009.
In December of 2009, Zoll (Nasdaq: ZOLL) won U.S. Food and Drug Administration 510(k) clearance for its Zoll E Series Monitor/Defibrillator with carbon monoxide monitoring.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
